At-home cervical screening tests offered in England
The DIY test kits, available from January, contain a long cotton-wool bud to swab the lining of the vagina.
The test is for human papillomavirus (HPV), which causes most cervical cancers, and women between the ages of 25 and 64 are offered it every few years.
But more than five million women aren't up to date with the test, according to the government.
The Department for Health and Social Care in England said the scheme would tackle "deeply entrenched barriers" that keep women away from cervical screening.
This can be due to embarrassment, discomfort, lack of time as well as religious or cultural concerns.
Just 68.8% of women currently take up the offer of cervical cancer screening - well below the NHS England target of 80%.
Younger women, those with a disability, ethnic minority communities and LGBT+ groups are more likely to miss appointments.
A recent trial showed the rollout of home test kits across England could increase the proportion screened to 77% over three years.
The Department of Health said women who had rarely or never attended cervical screening would be offered a self-sample kit to complete at home.
The kits are sent out "in discreet packaging" and the return postage is pre-paid.
The test checks for HPV alone, but if that's detected then women will be invited for to see a doctor who will check for cell changes which could indicate cancer.
Health and Social Care secretary Wes Streeting said: "We know the earlier cancer is diagnosed the better the chances are of survival.
"By making screening more convenient, we're tackling the barriers that keep millions of women from potentially life-saving tests."
Michelle Mitchell, chief executive of Cancer Research UK, said "beating cervical cancer means beating it for everyone" adding that at-home testing "helps to bring us closer to that goal".
Hazel Stinson, 49, from Kent, suffers from chronic fatigue syndrome and was last able to visit the GP for a cervical screening six years ago.
She says she is "absolutely thrilled" that at-home testing is being rolled out across England.
"This will mean that I and millions of other people just like me will be able to have the test when otherwise they might not be able to do it," she added.
Ms Stinson said as someone with chronic fatigue, which is also known as myalgic encephalomyelitis or ME, "the most important thing is to advocate for yourself".
She says she has always been left "feeling fearful" that her inability to attend the GP regularly for tests like cervical screening could really affect her health.
"I'm unwell enough as it is - I really don't want anything else on top of this," she explained.
NHS England recently announced a separate change to the timing of cervical screening invitations.
If women aged 25-49 have a negative test for HPV from this summer, they will wait five years until their next screening appointment instead of three. Research shows they're at very low risk of cervical cancer and can safely wait longer to be screened again.
vaginal bleeding that's unusual for you – including during or after sex, between periods or after the menopause - or heavier periods than usual
changes to vaginal discharge
pain during sex or in the lower back, lower tummy or between the hip bones (pelvis)
Source: NHS
DIY kits may see million more cervical-cancer tests
Vaccines could mean only one smear test a lifetime
Cervical screening invites to change in England
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
8 hours ago
- Forbes
A Regulated Trip: What New Mexico's Psilocybin Law Means For Work
Magic mushrooms are now medicine in New Mexico. And that shift could have ripple effects in the workplace. This spring, Governor Michelle Lujan Grisham signed Senate Bill 219, the Medical Psilocybin Act, into law, making New Mexico the third state to legalize psilocybin for medical use. Unlike Oregon and Colorado, which adopted their psilocybin programs through ballot initiatives, New Mexico enacted its law through the legislative process. That distinction is more than procedural. It reflects an institutional shift toward integrating psychedelic therapy into the framework of state-managed healthcare. The law took effect on June 20, 2025, and requires full program implementation by December 31, 2027. With that, New Mexico becomes the first state to create a clinician-administered psilocybin program governed by medical oversight, not consumer access. As psilocybin therapy enters a regulated medical model, employers must now examine how psilocybin intersects with workplace safety, disability accommodation, and drug policy enforcement. Psilocybin's Reintroduction as Medicine Psilocybin is a naturally occurring psychedelic compound found in certain mushrooms. Once ingested, it metabolizes into psilocin, which affects cognition, mood, and perception. Although it remains a Schedule I substance under federal law, psilocybin has reemerged over the past decade as a potential breakthrough therapy for severe mental health conditions. Peer-reviewed research continues to highlight its therapeutic potential in treating major depression, PTSD, substance use disorders, and end-of-life distress. New Mexico's legislation embraces this emerging science by establishing a medical-use program in which licensed clinicians, not dispensaries, administer psilocybin in approved therapeutic settings. The Department of Health is responsible for creating treatment protocols, licensing standards, clinician training, and oversight mechanisms. The Act also establishes both a research fund and a treatment equity fund to expand access and support clinical study. Psychedelic wellness expert Cesar Marin sees the program as a reflection of how far public understanding has evolved. 'We're not talking about the free‑wheeling psychedelic trips of the 1960s anymore,' Marin says. 'We're seeing most states consider or enact some form of psychedelic policy reform, and that momentum helps people feel more comfortable with the intentional, therapeutic use of psilocybin.' Qualifying conditions are narrowly defined to include treatment-resistant depression, PTSD, substance use disorder, and terminal illness. All treatment must occur in controlled environments with preparatory and integration sessions surrounding the administration of psilocybin. Psilocybin and psilocin are removed from the state's list of Schedule I controlled substances when used in accordance with the law, and services provided under the Act are exempt from New Mexico's gross receipts tax. Legal Protections Without Workplace Requirements The Medical Psilocybin Act offers strong protections for individuals operating within its boundaries. Licensed clinicians, producers, and qualified patients cannot be prosecuted under state law, and individuals on probation or awaiting trial may participate in treatment without jeopardizing their legal status. However, the Act stops short of granting any employment-based rights. It does not require employers to accommodate psilocybin use, nor does it prevent adverse action based on lawful participation in the program. That omission is deliberate and significant. While patients may legally participate in psilocybin-assisted therapy under state law, the federal classification of psilocybin as a Schedule I substance remains unchanged. And unlike medical cannabis laws in some states, New Mexico's psilocybin law provides no employment protections, no retaliation standard, and no accommodation framework. Still, employers should not assume the workplace will remain untouched. A New Compliance Challenge for Employers 'New Mexico legalizing medical psilocybin is a huge step toward bringing these treatments out of the shadows and into mainstream medicine,' says Marin. 'When folks see local leaders endorsing these programs, it lowers the fear factor and makes it easier for someone who's curious to explore them.' That shift in perception could soon reach the workplace. Employers may begin receiving accommodation requests from individuals participating in medically supervised psilocybin therapy for conditions like PTSD, treatment-resistant depression, or substance use disorder. And while psilocybin remains a federally controlled substance, the conditions it treats are often considered disabilities under the Americans with Disabilities Act (ADA). That means employers have a legal obligation to engage in the interactive process when an employee discloses a disability and requests accommodation, even if the employee's treatment involves a Schedule I substance like psilocybin. The ADA does not require employers to accommodate federally illegal drug use, but it does require them to consider accommodations related to the underlying condition. Employers are not obligated to tolerate on-the-job impairment or excuse safety violations. Still, if an employee reports off-duty participation in a licensed psilocybin program tied to a recognized condition, a flat denial without further inquiry could invite scrutiny under disability discrimination laws. Testing vs. Impairment: Where Policy Meets Practicality Psilocybin presents unique challenges when it comes to workplace drug testing. Unlike THC or opioids, psilocin, the active compound after ingestion, is not included in most standard employment drug panels. That means employers may be flying blind when it comes to detecting recent psilocybin use unless they specifically request an expanded panel. 'A person can be actively hallucinating due to psilocybin use and still pass a standard workplace drug test,' says Dr. Todd Simo, Chief Medical Officer at HireRight. 'Psilocin, the active compound, doesn't show up in most drug panels unless an employer specifically includes it. That's why training managers to recognize signs of impairment and providing a clear path to escalate reasonable suspicion are more effective strategies. For employers especially concerned, developing a reasonable suspicion panel that includes psilocybin and disclosing it to employees in advance can also help mitigate misuse.' Given that reality, employers may want to prioritize impairment-based enforcement strategies over reliance on traditional drug screening. While testing has its place, especially in post-accident investigations or in regulated industries, training supervisors to recognize signs of real-time impairment and respond consistently under internal policy is likely a more practical approach for most workplaces. Preparing for Disclosure and Dialogue Employers should take this opportunity to review and, where necessary, revise internal policies addressing drug and alcohol use, workplace impairment, and reasonable accommodations. Clarity around off-duty substance use and on-duty safety expectations will be essential. HR teams should also ensure that accommodation request procedures are equipped to handle emerging treatment disclosures, particularly where mental health conditions are involved. Equally important is creating an environment in which employees feel safe discussing mental health. Psilocybin's path to medical legitimacy mirrors, in many ways, the evolution of medical cannabis and broader mental health parity. For employers, staying ahead of these developments will require not only legal awareness but organizational empathy. The Bigger Picture New Mexico's Medical Psilocybin Act signals more than therapeutic access. It reflects a policy evolution, one where lawmakers, not just voters, are beginning to treat psychedelic medicine as a legitimate part of behavioral healthcare. The state's approach shifts the narrative from stigma to structure, putting psilocybin in the hands of trained clinicians operating under medical oversight. And while the law places no new obligations on employers, it surfaces a timely question: what does it mean to support mental health in a world where the frontier of treatment is changing? For employers, that shift invites action. It's time to revisit drug policies, reconsider testing strategies, and refine accommodation practices. As state-level momentum builds around psychedelics, employers don't need to endorse these therapies, but they do need to understand them. Because in the modern workplace, curiosity can be a better compliance strategy than surprise.
Yahoo
a day ago
- Yahoo
Common Viruses May Wake Dormant Breast Cancer Cells, Study Finds
Breast cancer patients who have been in remission for years or even decades may still need to be cautious about respiratory infections. Some common viruses may re-awaken a very small number of dormant breast cancer cells within our lungs, according to emerging research. "Dormant cancer cells are like the embers left in an abandoned campfire, and respiratory viruses are like a strong wind that reignites the flames," argues molecular geneticist James DeGregori from the University of Colorado. Related: The research began following the COVID-19 pandemic, when DeGregori and his colleagues began to notice a curious uptick in cancer cases. To find out more, the international team turned to human population studies and mouse models. They found that patients in remission for cancer in the UK Biobank who tested positive for SARS-CoV-2 later showed a twofold increase in cancer-related death. "The extent of this increased risk is almost unheard of in epidemiology for cancer," says epidemiologist Roel Vermeulen from Utrecht University in The Netherlands. "It's a significant effect." That's not all researchers found, either. Analyzing a separate breast cancer database from the United States, including nearly 37,000 patients, they discovered that a previous SARS-CoV-2 infection was associated with a greater than 40 percent increased risk of metastatic breast cancer in the lungs. Studies in mice suggest that viruses might be behind the spread. Influenza and SARS-CoV-2 infections triggered dormant breast cancer cells in mice to proliferate after only days of infection. Within two weeks, there was "a massive expansion of carcinoma cells into metastatic lesions" by more than 100-fold, write the authors, led by molecular geneticist Shi Chia from the University of Colorado. "Although species differences warrant caution in interpreting mouse data… collectively, these findings underscore the substantial metastatic risk COVID-19 posed to cancer survivors," warn the team. For years now, scientists have suspected that some highly common viruses, like the Epstein-Barr Virus (EBV), have the potential to trigger certain cancers. The human papillomavirus (HPV) is already known to do this. That's why the HPV vaccine has proved so life-changing for millions. It prevents deadly, viral-associated diseases, like cervical cancer. Since 1936, scientists have been searching for a virus that triggers breast cancer in a similar way, mostly in mice and human population studies. High-risk viruses have been detected in human breast cancer samples. EBV, for instance, is five times higher in breast cancer tissue than in normal tissue. But while the idea that viruses may predispose us to cancer is plausible, research in human cells is limited, and the mechanism underlying the disease spread remains undetermined. The immune system's response to viruses could possibly play a role. After initial remission, a tiny number of breast cancer cells can remain dormant in lung, bone, and liver tissue. Sometimes, inflammation can wake these cancer cells up – and viral respiratory infections, like the flu and COVID-19, can cause inflammation. In the current mouse experiments, the influenza A virus only reawakened dormant cancer cells in the lung if they triggered an increase in inflammatory cytokines, such as IL-6. The same was true of the coronavirus. The findings suggest that the immune system's response to viruses breeds the perfect environment for cancer to proliferate. "What our data suggest is that if you are a cancer patient who has these dormant cells, you may end up living a normal life and dying with these dormant cells, instead of dying because those dormant cells awakened," says DeGregori. "But if you get a respiratory virus like influenza or COVID, your chance of dying from those dormant cells awakening is much greater." If that's true, then it will be vital to protect the millions of breast cancer survivors out there who may face an increased risk of relapse if they get sick. Further research is needed to see if vaccination against influenza or COVID-19 can help. The study was published in Nature. Related News Study Reveals The Shocking Amount of Plastic We Breathe in Every Day Researchers Identified New Blood Group After 50 Year Mystery Sleepiness Could Be Triggered by a Power Overload in Our Brain Solve the daily Crossword
Epoch Times
a day ago
- Epoch Times
NIH Scientists Find a Type of HPV Can Cause Skin Cancer
A virus can cause skin cancer, scientists with the National Institutes of Health (NIH) said in new research published on July 30. A type of human papillomavirus (HPV) that is commonly found on the skin can cause skin cancer, the scientists said in a report published by The New England Journal of Medicine.
